Abixaban dosage for patient presented with CHF and Atrial fibrillation
Reading File
Finding Sources
Searching PubMed
apixaban atrial fibrillation heart failure dosing
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have all the data needed for a thorough answer. Let me compile the complete response.
Apixaban Dosing in CHF + Atrial Fibrillation
Note: You likely meant Apixaban (brand name Eliquis) - there is no drug called "Abixaban." This is a Factor Xa inhibitor and a first-line DOAC for stroke prevention in non-valvular atrial fibrillation.
Standard Dosing
| Regimen | Dose |
|---|---|
| Standard dose | 5 mg orally twice daily |
| Reduced dose | 2.5 mg orally twice daily |
Dose Reduction Criteria (the "2-of-3 Rule")
Reduce to 2.5 mg twice daily if the patient meets at least 2 of the following 3 criteria:
- Age ≥ 80 years
- Body weight ≤ 60 kg
- Serum creatinine ≥ 1.5 mg/dL
If only one criterion is met, use the standard 5 mg twice daily dose.
CHF and Atrial Fibrillation - Specific Considerations
Heart failure is a CHA2DS2-VASc risk factor (1 point). A patient with CHF + AF will almost always have a CHA2DS2-VASc score ≥ 2, making anticoagulation strongly recommended.
Why apixaban is preferred in CHF:
- In the ARISTOTLE trial, apixaban 5 mg twice daily vs. warfarin showed:
- Combined ischemic/hemorrhagic stroke or systemic embolism: 1.27% vs. 1.6% (p < 0.001 for noninferiority; p < 0.01 for superiority)
- Major bleeding was reduced by ~1%, favoring apixaban (p < 0.001)
- DOACs including apixaban are strongly preferred over warfarin in non-valvular AF patients
- Apixaban has only 25% renal elimination (lowest among DOACs), making it safer in patients with mild-moderate renal impairment, which is common in CHF
When NOT to Use Apixaban (Contraindications / Special Cases)
| Situation | Recommendation |
|---|---|
| Mechanical prosthetic heart valve | Use warfarin only - DOACs are contraindicated |
| Rheumatic mitral stenosis | Use warfarin only |
| Severe renal failure (eGFR < 15 mL/min or on dialysis) | Warfarin titrated to INR 2.0-3.0 |
| Active significant bleeding | Hold anticoagulation |
Reversal Agent
If major bleeding occurs on apixaban, the reversal agent is andexanet alfa (400-800 mg IV bolus over 15-30 min, followed by a 400-960 mg infusion), which achieves good-to-excellent hemostasis in ~75% of patients within 12 hours.
Summary
For a typical CHF + AF patient (non-valvular):
- Apixaban 5 mg PO twice daily is the standard dose
- Reduce to 2.5 mg PO twice daily only if 2 or more of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL
- Heart failure itself scores 1 point on CHA2DS2-VASc, making anticoagulation mandatory at most score thresholds
Sources: Goldman-Cecil Medicine, 26th Ed.; Harrison's Principles of Internal Medicine, 22nd Ed. (2025); Braunwald's Heart Disease
This is a shared conversation. Sign in to Orris to start your own chat.